Amprion Awarded NIH Grant For Analytical Validation of SYNTap® Biomarker Test For Neurological Disease
Thanks to additional research funding from NIH/NINDS, Amprion
SYNTap® Biomarker Test
The SYNTap Test helps physicians diagnose synucleinopathies such as: Parkinson’s, LBD, Alzheimer’s with Lewy Bodies, MCI, and MSA.
This website is intended for the informational purposes of healthcare professionals.
Parkinson’s Disease
How the SYNTap Test helps improve diagnostic accuracy for various types of Parkinson's.
Lewy Body Dementia
How the SYNTap Test can improve the diagnostic challenges of Lewy Body Dementia.
AD with Lewy Bodies
How the SYNTap Test helps differentiate the Alzheimer's variant: AD with Lewy Bodies.
Multiple System Atrophy
How the SYNTap Test helps physicians differentiate MSA from Parkinson's disease.
MCI with Lewy Bodies
How the SYNTap Test helps detect Minimal Cognitive Impairment with Lewy Bodies early.
Download Spec. Sheet
Details on the SYNTap Biomarker Test performance characteristics.
Explore Our Science
A pioneer of Prion Detection Science®, Amprion innovates biomarker testing to accurately detect misfolded proteins associated with brain diseases.
After decades of research, Amprion is thrilled to rollout its impactful discoveries from the lab to the world.
Amprion in the News
SYNTap Biomarker Test helps doctors distinguish Parkinson’s from Parkinsonism in early stages
For the first time in history, Amprion’s breakthrough
Amprion Announces Commercial Rollout of the SYNTap Test at the AAN Annual Meeting and the Formation of Clinical Advisory Board
We invite AAN Annual Meeting attendees to visit
